Payment overview · 2025
General Payments
$30,051.06
105 reported records · 18 companies
Healthcare provider profile · identity verified
Bruce Edward Wilson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · RICHLAND, WA · NPI 1295826857
Verified facts
What the public records show
CMS Open Payments records show Bruce Edward Wilson, M.D. received $30,051.06 in general payments during 2025 across 105 reported records.
Novo Nordisk Inc accounted for 61.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 889 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lantus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18,606.68 | 61.9% | 34 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $7,266.08 | 24.2% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $3,178.59 | 10.6% | 11 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $191.61 | 0.6% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $147.51 | 0.5% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $113.62 | 0.4% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.21 | 0.3% | 4 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $74.70 | 0.2% | 4 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $69.10 | 0.2% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $65.98 | 0.2% | 3 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $49.15 | 0.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $47.07 | 0.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.77 | 0.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $32.51 | 0.1% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $24.94 | 0.1% | 1 | 2025 |
| Soleno Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.49 | 0.1% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.09 | 0.1% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $22.96 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,002.44 | 7 |
| Consulting Fee | $5,250.00 | 1 |
| Travel and Lodging | $3,177.81 | 8 |
| Food and Beverage | $2,870.81 | 87 |
| Compensation for serving as faculty or as a speaker for a medical education program | $750.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17,517.95 | 26 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $7,266.08 | 13 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $2,219.94 | 8 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $191.61 | 10 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $159.96 | 13 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $158.73 | 7 | 2025 |
Source payment records
|
|||||
| LOKELMA Normalized: lokelma |
Drug | AstraZeneca Pharmaceuticals LP | $147.51 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $113.62 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $93.20 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $74.70 | 4 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $69.10 | 3 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $65.98 | 3 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $49.15 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $47.07 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $38.74 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $38.47 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $36.77 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $32.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.45 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $24.94 | 1 | 2025 |
Source payment records
|
|||||
| VYKAT XR Normalized: vykat xr |
Drug | Soleno Therapeutics, Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $22.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 325 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 889 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
120 | 34 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
117 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
325 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
325 | 84 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
60 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
889 | 168 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ozempic | Semaglutide | 889 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 586 | 156 |
| Metformin Hcl | Metformin Hcl | 479 | 131 |
| Jardiance | Empagliflozin | 325 | 84 |
| Tresiba Flextouch U-200 | Insulin Degludec | 206 | 53 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 165 | 48 |
| Metformin Hcl Er | Metformin Hcl | 136 | 38 |
| Lisinopril | Lisinopril | 123 | 35 |
| Synthroid | Levothyroxine Sodium | 120 | 34 |
| Farxiga | Dapagliflozin Propanediol | 117 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 114 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 35 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 101 | 40 |
| Testosterone Cypionate | Testosterone Cypionate | 94 | 22 |
| Humalog Kwikpen U-100 | Insulin Lispro | 88 | 34 |
| Humalog | Insulin Lispro | 86 | 21 |
| Methimazole | Methimazole | 80 | 24 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 27 |
| Simvastatin | Simvastatin | 76 | 21 |
| Novolog Flexpen | Insulin Aspart | 67 | 25 |
| Losartan Potassium | Losartan Potassium | 64 | 19 |
| Mounjaro | Tirzepatide | 61 | 16 |
| Trulicity | Dulaglutide | 60 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 18 |
| Glimepiride | Glimepiride | 54 | 14 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 46 | 12 |
| Prednisone | Prednisone | 41 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 39 | 15 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 38 | 17 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Novolog | Insulin Aspart | 37 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Hydrocortisone | Hydrocortisone | 30 | suppressed |
| Ezetimibe | Ezetimibe | 28 | 11 |
| Levemir Flexpen | Insulin Detemir | 27 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Prolia | Denosumab | 24 | 15 |
| Omeprazole | Omeprazole | 23 | suppressed |
| Invokana | Canagliflozin | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Gabapentin | Gabapentin | 16 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30,051.06 · 105 records | Novo Nordisk Inc | CRENESSITY, CREON, EVENITY, FREESTYLE LIBRE 3, GVOKE HYPOPEN, ISTURISA, JARDIANCE, Korlym, LEQVIO, LOKELMA, MOUNJARO, Ozempic, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, STRENSIQ, TEPEZZA, TWIIST, TZIELD, VYKAT XR, Wegovy, ZEPBOUND, t:slim X2 Insulin Pump with Control-IQ | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error